GlassScriptPhysician profile
Barbara J Arnold
NPI 1487701850
$4,659.01
in general payments reported to CMS, 2019-2025
22 companies · $1,013 in 2025
The $1,013 reported for 2025 was more than what 77% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $610 · 2020: $395 · 2021: $574 · 2022: $340 · 2023: $918 · 2024: $809 · 2025: $1,013.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,740.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,740.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $785.95 | 2019-2025 | Centurion, Rocklatan, Rhopressa |
| Mallinckrodt Hospital Products INC. | $641.87 | 2020-2024 | Acthar |
| Genentech USA, INC. | $544.94 | 2022-2025 | Vabysmo, Susvimo |
| Biotissue Holdings INC. | $345.72 | 2024 | |
| Apellis Pharmaceuticals, INC. | $344.81 | 2023-2025 | Syfovre |
| Abbvie INC. | $337.70 | 2019-2025 | Durysta, Vuity |
| Novartis Pharmaceuticals Corporation | $257.61 | 2019-2022 | |
| Aerie Pharmaceuticals, INC. | $236.71 | 2019-2021 | |
| Allergan, INC. | $178.77 | 2020-2022 | |
| Horizon Therapeutics Plc | $171.79 | 2022-2023 | Tepezza |
| Alexion Pharmaceuticals, INC. | $123.59 | 2025 | Ultomiris |
| Genentech, INC. | $121.74 | 2025 | Vabysmo |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $120.69 | 2019 | |
| Kala Pharmaceuticals, INC. | $119.06 | 2021 | |
| Zimmer Biomet Holdings, INC. | $112.81 | 2019 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tarsus Pharmaceuticals, INC. | $58.74 | 2024-2025 | Xdemvy |
| Amgen INC. | $45.24 | 2024-2025 | Tepezza |
| Boston Scientific Corporation | $32.81 | 2023 | |
| Dompe US, INC. | $25.51 | 2024 | Oxervate |
| Bausch & Lomb Americas INC. | $20.65 | 2025 | Vyzulta |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Sanofi Pasteur INC. | $12.90 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Barbara Arnold listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.